MX2021015537A - Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida. - Google Patents

Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.

Info

Publication number
MX2021015537A
MX2021015537A MX2021015537A MX2021015537A MX2021015537A MX 2021015537 A MX2021015537 A MX 2021015537A MX 2021015537 A MX2021015537 A MX 2021015537A MX 2021015537 A MX2021015537 A MX 2021015537A MX 2021015537 A MX2021015537 A MX 2021015537A
Authority
MX
Mexico
Prior art keywords
domain
heavy chain
chain variable
variable domain
multivalent
Prior art date
Application number
MX2021015537A
Other languages
English (en)
Inventor
Johannes Auer
Monika Popp
Christina-Lisa Hoeck
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2021015537A publication Critical patent/MX2021015537A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Abstract

En la presente se informa un método para producir un anticuerpo biespecífico multivalente que comprende las etapas de cultivar una célula de mamífero que comprende un ácido desoxirribonucleico que codifica el anticuerpo biespecífico multivalente, y recuperar el anticuerpo biespecífico multivalente de la célula o el medio de cultivo, en donde el ácido desoxirribonucleico que codifica el anticuerpo biespecífico multivalente se integra de manera estable en el genoma de la célula de mamífero y comprende en la dirección 5' a 3' un primer casete de expresión que codifica la primera cadena pesada, un segundo casete de expresión que codifica la primera cadena liviana, un tercer casete de expresión que codifica la primera cadena liviana, un cuarto casete de expresión que codifica la segunda cadena pesada, un quinto casete de expresión que codifica la primera cadena liviana y un sexto casete de expresión que codifica la primera cadena liviana, en donde la primera cadena pesada comprende, del extremo N a C, un primer dominio variable de la cadena pesada, un dominio CH1, un primer dominio variable de la cadena pesada, un dominio CH1, una región bisagra, un dominio CH2, un dominio CH3 y un primer dominio variable de la cadena liviana, la segunda cadena pesada comprende, del extremo N a C, un primer dominio variable de la cadena pesada, un dominio CH1, un primer dominio variable de la cadena pesada, un dominio CH1, una región bisagra, un dominio CH2, un dominio CH3 y un segundo dominio variable de la cadena pesada, y la primera cadena liviana comprende, del extremo N a C, un segundo dominio variable de la cadena liviana y un dominio CL, en donde el primer dominio variable de la cadena pesada y el segundo dominio variable de la cadena liviana forman un primer sitio de unión y el segundo dominio variable de la cadena pesada y el primer dominio variable de la cadena liviana forman un segundo sitio de unión.
MX2021015537A 2019-06-19 2020-06-17 Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida. MX2021015537A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19181098 2019-06-19
PCT/EP2020/066687 WO2020254356A1 (en) 2019-06-19 2020-06-17 Method for the generation of a multivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization

Publications (1)

Publication Number Publication Date
MX2021015537A true MX2021015537A (es) 2022-02-10

Family

ID=67060258

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021015537A MX2021015537A (es) 2019-06-19 2020-06-17 Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.

Country Status (11)

Country Link
US (1) US20220169731A1 (es)
EP (1) EP3986927A1 (es)
JP (2) JP2022537202A (es)
KR (1) KR20220010549A (es)
CN (1) CN113993887A (es)
AU (1) AU2020297940A1 (es)
BR (1) BR112021025500A2 (es)
CA (1) CA3140323A1 (es)
IL (1) IL288965A (es)
MX (1) MX2021015537A (es)
WO (1) WO2020254356A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382696B (zh) * 2017-03-07 2024-04-19 豪夫迈·罗氏有限公司 发现替代性抗原特异性抗体变体的方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
JP3150340B2 (ja) 1990-11-13 2001-03-26 イムネクス コーポレイション 二機能選択可能融合遺伝子
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
EP0804590A1 (en) 1993-05-21 1997-11-05 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2637801T3 (es) 2000-04-11 2017-10-17 Genentech, Inc. Anticuerpos multivalentes y usos de los mismos
BRPI0513706A (pt) 2004-07-20 2008-05-13 Symphogen As anticorpo policlonal recombinante anti-rhesus d e métodos de produção
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2414391B1 (en) 2009-04-02 2018-11-28 Roche Glycart AG Multispecific antibodies comprising full length antibodies and single chain fab fragments
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
AU2010252284A1 (en) 2009-05-27 2011-11-17 F. Hoffmann-La Roche Ag Tri- or tetraspecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
FI2726510T3 (fi) 2011-05-27 2023-05-04 Hoffmann La Roche Kaksoiskohdennus
WO2013006142A1 (en) 2011-07-05 2013-01-10 Nanyang Technological University A novel process and reagent for rapid genetic alterations in eukaryotic cells
CN108271377B (zh) * 2015-10-07 2021-11-19 豪夫迈·罗氏有限公司 具有针对共刺激性tnf受体的四价的双特异性抗体
US11530277B2 (en) * 2016-04-20 2022-12-20 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of an expression-enhancing locus
MA48723A (fr) 2017-03-10 2020-04-08 Hoffmann La Roche Procédé de production d'anticorps multispécifiques
WO2019086497A2 (en) 2017-11-01 2019-05-09 F. Hoffmann-La Roche Ag Combination therapy with targeted ox40 agonists

Also Published As

Publication number Publication date
IL288965A (en) 2022-02-01
WO2020254356A1 (en) 2020-12-24
BR112021025500A2 (pt) 2022-02-01
CN113993887A (zh) 2022-01-28
AU2020297940A1 (en) 2021-12-16
JP2024016181A (ja) 2024-02-06
KR20220010549A (ko) 2022-01-25
EP3986927A1 (en) 2022-04-27
JP2022537202A (ja) 2022-08-24
CA3140323A1 (en) 2020-12-24
US20220169731A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
EA200900286A1 (ru) Модификация бактерий для получения этанола
NO20080001L (no) Fremgangsmate til fremstilling av av 1,3-propanediol fra glycerol, et biprodukt fra fremstilling av biodiesel
CR20190309A (es) Moleculas de unión de3 antígeno biespecíficas que comprenden el clon 20h4.9 anti-4-1bb
NZ592308A (en) Non-human mammals for the production of chimeric antibodies
MX2022008124A (es) Anticuerpo que se une a grupo de diferenciacion 3 (cd3) humano.
IL299221A (en) CD3 binding antibodies
AR107902A2 (es) Anticuerpos anti-cd37
SG171577A1 (en) Methods for producing yeast-based vaccines
CA2808482C (en) Methods for the generation of multispecific and multivalent antibodies
HRP20090228T1 (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
WO2007064724A3 (en) Plants having improved growth characteristics and methods for making the same
WO2004058820A3 (en) Single-domain-effector group and its uses
NZ592036A (en) Methods for producing antibodies from plasma cells
GB2460810A (en) Transgenic non-human mammal with homodimeric vh binding complex
ATE333509T1 (de) Methoden und materialien zur synthese von organischen produkten
UA91335C2 (ru) Растения, имеющие повышенную урожайность, и способ их получения
MX2021015537A (es) Metodo para la generacion de una celula que expresa anticuerpo biespecifico multivalente mediante la integracion diana de casetes de expresion multiples en una organizacion definida.
DE602006021324D1 (de) Verfahren zur herstellung stabiler b-lymphozyten
ATE326523T1 (de) Verfahren zur fermentativen herstellung von l- methionin
MX2021015538A (es) Metodo para la generacion de una celula que expresa un anticuerpo biespecifico bivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
MX2021015648A (es) Metodo para la generacion de una celula que expresa un anticuerpo multiespecifico multivalente mediante integracion dirigida de multiples casetes de expresion en una organizacion definida.
MX2021015540A (es) Metodo para la generacion de una celula que expresa un anticuerpo trivalente mediante la integracion dirigida de multiples casetes de expresion en una organizacion definida.
WO2008015662A8 (en) A method of producing recombinant biological products
RU2017127208A (ru) Строение экспрессионного вектора, новые способы получения клеток-продуцентов и их применение для рекомбинантного получения полипептидов
TW200506059A (en) Method for obtaining mastocyte lines from pig tissues and for producing heparin-type molecules